Published June 10, 2026
Deadline July 15, 2026 at 23:59, Eastern Standard Time
Category: Grants, Fellowships
Locations: Germany
Pfizer is accepting proposals for the Transthyretin Cardiac Amyloidosis Fellowship Grant through its competitive grant program using an internal review process. Eligible German based institutions are encouraged to review the details below and submit their applications before the deadline.
Program Overview
This competitive program seeks to promote the importance of training healthcare professionals to recognize, diagnose, treat and monitor ATTR cardiac amyloidosis and to foster research in this field. The grant intends to support institutions with strong experience in the management of ATTR cardiac amyloidosis patients who are willing to guide and educate a fellow physician in order to develop an in depth understanding of the diagnosis, treatment and monitoring of ATTR patients.
Geographic Scope
Germany
Funding Range And Project Length
Grant funding is available to support one fellow for up to 6 months up to €50,000. The budget can only include salary and support of the fellow benefits. Grant funds cannot be used for overhead or indirect costs, food and beverage, travel expenses, rent or accommodation of the fellow. Funding will be awarded to the institution not an individual.
Key Milestones
The submission deadline is July 15 2026. Anticipated grant award notification is in September 2026. Anticipated project start date is November 2026. Anticipated project end date is May 2027.
Eligibility Requirements
Applicants must be German based institutions. The name of the potential fellow must not be included in application materials. This grant will be awarded to an institution not an individual.
Institutions must have fellowship programs that include a strong mentoring program and potentially independent research. Clinical training must be included in the program. Examples of clinical training include active participation in diagnosis, treatment and monitoring of ATTR amyloidosis patients and suspect patients, educational time with an interdisciplinary team in review of case examples and relevant didactic training, and use of tools for improvement in patient health for specific therapeutic areas or conditions.
No aspect of the fellowship program can benefit Pfizer business or a Pfizer asset. Examples of research that would not be eligible include research involving the study or evaluation of any pharmaceutical product and basic science or fundamental research in animal models or in vitro. Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.
Specific Area Of Interest
The grant seeks to support clinical training fellowship programs at institutions with strong experience in the management of ATTR cardiac amyloidosis patients who are willing to guide and educate a fellow physician to develop an in depth understanding of the diagnosis, treatment and monitoring of ATTR patients. The grant will be awarded based on the strength of the requesting organisation ability to provide training and guidance to the fellow.
Requirements For Prospective Fellows
The institution must ensure that any fellow receiving grant funds must be a German Worker meaning a German citizen, permanent resident, refugee or asylee, or hold an appropriate non immigrant visa status authorizing employment in Germany. As a condition of the grant the selected fellow will be named in transparency reporting as a recipient of grant funding.
Submission Process
Applications must be submitted through the Pfizer Cybergrants portal at www.cybergrants.com/pfizer/GMGFellowship. First time users should click Create Your Password. Applicants should click the Start A New Fellowship Application button.
For the question Competitive Grant select Yes. For Primary Area of Interest select CVM ATTR CM. For Competitive Grant Program Name select 2026 Germany Cardiac Amyloidosis Fellowship. The proposal must be uploaded using the required Proposal Template.
Questions And Support
For technical difficulties with the website applicants should click the Technical Questions link. For questions regarding the request for proposals direct inquiries in writing to the Grant Officer Nicola Fenderico at [email protected] with the subject line 2026 Transthyretin Cardiac Amyloidosis Fellowship.
Review And Approval Process
This request for proposals uses an internal review panel to make the final grant decision. Proposals will be evaluated based on fellowship objectives, medical needs, ATTR CM patient care experience, mentoring and training opportunities, and resources. All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification during the review period.
Application Deadline
July 15, 2026 at 23:59, Eastern Standard Time
More Details: Pfizer Fellowship Grant Program
